Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera

Blood

Volumn 112, Issue 8, 2008, Pages 3065-3072

  Kiladjian, Jean Jacques ^a   Cassinat, Bruno ^b   Chevret, Sylvie ^b   Turlure, Pascal ^c   Cambier, Nathalie ^d   Roussel, Murielle ^e   Bellucci, Sylvia ^f   Grandchamp, Bernard ^g   Chomienne, Christine ^b   Fenaux, Pierre ^a  

^a AVICENNE HOSPITAL   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c DUPUYTREN UNIVERSITY HOSPITAL   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e CHU PURPAN   (France)

^f HÔPITAL LARIBOISIÈRE   (France)

^g INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; PEGINTERFERON ALPHA2A; ALPHA2A INTERFERON; DRUG CARRIER; JAK2 PROTEIN, HUMAN; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A;

ADULT; ARTICLE; ASTHENIA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MONITORING; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOCRINE DISEASE; FATIGUE; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; LIBIDO DISORDER; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCULOSKELETAL PAIN; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; POLYCYTHEMIA VERA; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; SKIN TOXICITY; UNSPECIFIED SIDE EFFECT; BLOOD; GENETICS; HETEROZYGOSITY LOSS; MIDDLE AGED; MUTATION; REMISSION; TIME; TREATMENT OUTCOME;

ADULT; DRUG CARRIERS; FEMALE; HUMANS; INTERFERON ALFA-2A; JANUS KINASE 2; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; MUTATION; POLYCYTHEMIA VERA; POLYETHYLENE GLYCOLS; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 54049141336     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-03-143537     Document Type: Article

References (49)

1. Vainchenker W, Constantinescu SN. A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases. Hematology Am Soc Hematol Educ Program. 2005: 195-200.
2. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110:1092-1097.
3. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005:365: 1054-1061.
4. James C, Delhommeau F, Marzac C, et al. Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis. Leukemia. 2006;20:350-353.
5. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-1790.
6. Levine RL, Wadleigh M, Gools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387-397.
7. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia. 2007;21:1952-1959.
8. Jones AV, Silver RT, Waghorn K, et al. Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. Blood. 2006;107:3339-3341.
9. Kiladjian JJ, Cassinat B, Turlure P, et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood. 2006;108:2037-2040.
10. Finazzi G, Barbui T. How I treat patients with polycythemia vera. Blood. 2007; 109:5104-5111.
11. Mesa RA. Navigating the evolving paradigms in the diagnosis and treatment of myeloproliferative disorders. Hematology Am Soc Hematol Educ Program. 2007;2007:355-362.
12. Barbui T, Barosi G, Grossi A, et al. Practice guidelines for the therapy of essential thrombocythemia: a statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica. 2004;89: 215-232.
13. Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood. 2005;105:2664-2670.
14. Kiladjian JJ, Rain JD, Bernard JF, Briere J, Chomienne C, Fenaux P. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia. Semin Thromb Hemost. 2006;32:417-421.
15. McMullin MF, Bareford D, Campbell P, et al. Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br J Haematol. 2005;130:174-195.
16. Silver RT. Recombinant interferon-alpha for treatment of polycythaemia vera. Lancet. 1988;2:403.
17. Liu E, Jelinek J, Pastore YD, Guan Y, Prchal JF, Prchal JT. Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin. Blood. 2003;101:3294-3301.
18. Massaro P, Foa P, Pomati M, et al. Polycythemia vera treated with recombinant interferon-alpha 2a: evidence of a selective effect on the malignant clone. Am J Hematol. 1997;56:126-128.
19. Messora C, Bensi L, Vecchi A, et al. Cytogenetic conversion in a case of polycythaemia vera treated with interferon-alpha. Br J Haematol. 1994;86:402-404.
20. Silver RT. Long-term effects of the treatment of polycythemia vera with recombinant interferonalpha. Cancer. 2006;107:451-458.
21. Alvarado Y, Cortes J, Verstovsek S, et al. Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia. Cancer Chemother Pharmacol. 2003;51:81-86.
22. Jabbour E, Kantarjian H, Gortes J, et al. PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study. Cancer. 2007;110:2012-2018.
23. Langer C, Lengfelder E, Thiele J, et al. Pegylated interferon for the treatment of high risk essential thrombocythemia: results of a phase II study. Haematologica. 2005;90:1333-1338.
24. Samuelsson J, Hasselbalch H, Bruserud O, et al. A phase ll trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life. Cancer. 2006;106:2397-2405.
25. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356:459-468.
26. Kralovics R, Guan Y, Prchal JT. Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp Hematol. 2002;30:229-236.
27. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350:114-124.
28. Gangat N, Strand J, Li CY, Wu W, Pardanani A, Tefferi A, Leucocytosis in polycythaernia vera predicts both inferior survival and leukaemic transformation. Br J Haematol. 2007:138:354-358.
29. Kiladjian JJ, Gardin C, Renoux M, Bruno F, Bernard JF. Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy. Hematol J. 2003;4:198-207.
30. Landolfi R, Di Gennaro L, Barbui T, et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood. 2007:109: 2446-2452.
31. Falanga A, Marchetti M, Vignoli A, Balducci D, Barbui T. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol. 2005;33:523-530.
32. Falanga A, Marchetti M, Vignoli A, et al. V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules. Exp Hematol. 2007;35:702-711.
33. Passamonti F, Rumi E, Pietra D, et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood. 2006;107:3676-3682.
34. Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23: 2224-2232.
35. Lengfelder E, Berger U, Hehlmann R. Interferon alpha in the treatment of polycythemia vera. Ann Hematol. 2000;79:103-109.
36. Quintas-Cardama A, Kantarjian H, Garcia-Manero G, et al. Pegylated interferon-alfa-2a (PEG-IFN-α-2A; PEGASYS) for essential thrombocythemia and polycythemia vera: an update of an ongoing phase II study [abstract]. Blood. 2007: 110:3542.
37. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005; 353:33-45.
38. Najean Y, Rain JD. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood. 1997;90:3370-3377.
39. Najean Y, Rain JD. Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. The French Polycythemia Study Group. Blood. 1997:89:2319-2327.
40. Wang YL, Vandris K, Jones A, et al. JAK2 mutations are present in all cases of polycythemia vera. Leukemia. 2008;22:1289.
41. Kiladjian JJ, Elkassar N, Cassinat B, et al. Essential thrombocythemias without V617F JAK2 mutation are clonal hematopoietic stem cell disorders. Leukemia. 2006;20:1181-1183.
42. Kralovics R, Teo SS, Li S, et al. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood. 2006;108:1377-1380.
43. Nussenzveig RH, Swierczek SI, Jelinek J, et al. Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol. 2007;35:32-38.
44. Ishii T, Xu M. Zhao Y, et al. Recurrence of clonal hematopoiesis after discontinuing pegylated recombinant interferon-alpha 2a in a patient with polycythemia vera. Leukemia. 2007;21:373-374.
45. Krause DS, Van Etten RA. Bedside to bench: interfering with leukemic stem cells. Nat Med. 2008;14:494-495.
46. Pestka S. The interferons: 50 years after their discovery, there is much more to learn. J Biol Chem. 2007;282:20047-20051.
47. Xiong Z, Liu E, Yan Y, et al. An unconventional antigen translated by a novel internal ribosome entry site elicits antitumor humoral immune reactions. J Immunol. 2006;177:4907-4916.
48. Xiong Z, Yan Y, Liu E, et al. Novel tumor antigens elicit anti-tumor humoral immune reactions in a subset of patients with polycythemia vera. Clin Immunol. 2007;122:279-287.
49. Pardanani A. JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia. 2008;22:23-30.